Last reviewed · How we verify
CC-2001
CC-2001 is a histone deacetylase inhibitor.
CC-2001 is a histone deacetylase inhibitor. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | CC-2001 |
|---|---|
| Also known as | Thalidomide, Thaliomid |
| Sponsor | Celgene |
| Drug class | Histone deacetylase inhibitor |
| Target | Histone deacetylase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Histone deacetylase inhibitors, such as CC-2001, work by blocking the action of histone deacetylases, which are enzymes that remove acetyl groups from histones. This leads to an increase in histone acetylation, which in turn promotes chromatin relaxation and increases gene expression. CC-2001 is being investigated for its potential to treat various types of cancer.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CC-2001 CI brief — competitive landscape report
- CC-2001 updates RSS · CI watch RSS
- Celgene portfolio CI